Consensus Viatris Inc.

Equities

VTRS

US92556V1061

Market Closed - Nasdaq Other stock markets 21:15:00 03/05/2024 BST			5-day change	1st Jan Change
11.78 ^USD	+1.55%		+1.82%	+8.77%

04-18	Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says	MT
04-18	UK Regulator to Consider Undertakings for Theramex-Viatris Deal	MT

Evolution of the average Target Price on Viatris Inc.

Price target over the last 5 years

History of analyst recommendation changes

7fde10ad56b8d56f30e5b39c13.WVi8wM_f8E6ddwENHz6s1kP8KNbxxEImtPXXIwGPtrg.LA7Zn_6MtXyvJUJZLVbD4Aq9cqSWjh1pzIW7Rni32ugjO--FkJPIfNY-WA~a898ece0e1bc62cd7fc3070b59bef42d

Analyst Recommendations on Viatris Inc.

Atomo Diagnostics Wins AU$570,000 HIV Self-Tests Order	04-15	MT
Stonex Group Insider Sold Shares Worth $488,142, According to a Recent SEC Filing	03-25	MT
India's Nifty 50 set to open at new record high, buoyed by strong growth data	12-01	RE
Piper Sandler Adjusts Viatris' Price Target to $11 From $10, Maintains Neutral Rating	11-22	MT
Another clue on monetary policy?	11-08
BofA Securities Downgrades Viatris to Underperform From Neutral, Adjusts Price Target to $9 From $13	23/10/23	MT
UBS Adjusts Viatris Price Target to $11 From $12, Maintains Neutral Rating	20/10/23	MT
Out with the old	02/10/23
Inflation, Interest-Rate Prospects Lift Wall Street Pre-Bell; Asia, Europe Off	07/08/23	MT
Barclays Downgrades Viatris to Underweight From Equalweight, Price Target is $11	23/06/23	MT
Fitch Affirms IDR of Viatris at 'BBB'; Outlook Stable	26/04/23	AQ
Barclays Downgrades Viatris to Equal Weight From Overweight, $11 Price Target	24/04/23	MT
Barclays Adjusts Price Target on Viatris to $16 From $15, Keeps Overweight Rating	28/02/23	MT
BMO Capital Downgrades Viatris to Market Perform From Outperform, Adjusts Price Target to $14 From $16	17/02/23	MT
Barclays Adjusts Price Target on Viatris to $15 From $16, Maintains Overweight Rating	01/02/23	MT
Jefferies Upgrades Viatris to Buy From Hold, Adjusts Price Target to $15 From $13	27/01/23	MT
Indian shares set for muted open ahead of GDP data	30/11/22	RE
UBS Upgrades Viatris to Neutral From Sell, Adjusts Price Target to $12 From $9	10/11/22	MT
Piper Sandler Upgrades Viatris to Neutral From Underweight, Price Target is $10	08/11/22	MT
Barclays Adjusts Viatris' Price Target to $16 From $21, Reiterates Overweight Rating	25/10/22	MT
Jefferies Starts Viatris at Hold With $11 Price Target	21/10/22	MT
BofA Securities Adjusts Viatris Price Target to $11 From $14, Maintains Neutral Rating	14/10/22	MT
BMO Capital Adjusts Viatris' Price Target to $16 From $19, Maintains Outperform Rating	09/08/22	MT
UBS Downgrades Viatris to Sell From Neutral, Adjusts Price Target to $9 From $12	14/06/22	MT
Piper Sandler Downgrades Viatris to Underweight From Neutral; Price Target is $10	10/05/22	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

11.78 USD

Average target price

12.46 USD

Spread / Average Target

+5.75%

High Price Target

14 USD

Spread / Highest target

+18.85%

Low Price Target

11 USD

Spread / Lowest Target

-6.62%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Viatris Inc.

Piper Sandler
BofA Securities
UBS
Barclays
BMO Capital
Jefferies & Co.
Citigroup
Raymond James
Truist Securities
JPMorgan Chase
Cowen
RBC Capital Markets
Goldman Sachs
J.P. Morgan Chase

Ratings for Viatris Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar